3-(1-甲基丙基)-吡啶 | 25224-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(1-甲基丙基)-吡啶
• 英文名称: 3-(2'-butyl)pyridine
• 英文别名: 3-s.butylpyridine；3-sek.-Butyl-pyridin；3-(2-n-Butyl)-pyridin；3-sec-butyl-pyridine；3-sec-Butyl-pyridin；3-sec-Butylpyridine；3-butan-2-ylpyridine
• CAS: 25224-14-0
• 化学式: C₉H₁₃N
• 分子量: 135.209
• InChiKey: UEOMUYCGCCSHAP-UHFFFAOYSA-N

物化性质

• 沸点：
  95-97 °C(Press: 15 Torr)
• 密度：
  0.906±0.06 g/cm3(Predicted)
• LogP：
  2.664 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  哌啶 以12%的产率得到
  参考文献：
  名称：

  JAYAMANI, M.;ANANTHAN, S.;PILLAI, C. N., INDIAN J. CHEM. B , 28,(1989) N, C. 131-132

  摘要：

  DOI：

文献信息

• DIPHENYL DERIVATIVES AND USES THEREOF
  申请人：NOVARTIS AG

  公开号：US20190077773A1

  公开（公告）日：2019-03-14

  The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

  本公开提供了一种公式(I)的化合物： 或其药用可接受的盐，以及其用于激活生长因子途径、促进伤口愈合、促进组织修复以及治疗听力损失、骨骼肌损失、器官退化、组织损伤、神经退化和肌肉萎缩的治疗用途。本公开还提供了药物组合物和组合物。本公开还涉及将此类化合物用于研究或其他非治疗目的。
• Iron-Catalyzed Isopropylation of Electron-Deficient Aryl and Heteroaryl Chlorides
  作者：James N. Sanderson、Andrew P. Dominey、Jonathan M. Percy

  DOI：10.1002/adsc.201601097

  日期：2017.3.20

  of secondary alkyl‐substituted aryl and heteroaryl chlorides challenge both selectivity and functional group tolerance. This contribution describes the use of statistical design of experiments to develop an effective procedure for the preparation of isopropyl‐substituted (hetero)arenes with minimal isopropyl to n‐propyl isomerization. The reaction tolerates electronically diverse aryl chloride coupling

  传统的制备仲烷基取代的芳基和杂芳基氯化物的方法对选择性和官能团耐受性都提出了挑战。这种贡献描述了使用的实验统计设计来开发用于制备异丙基取代的（杂）芳烃的具有最小异丙到一个有效的过程Ñ丙基异构化。该反应可耐受电子形式多样的芳基氯偶合体，对于电子含量极低的芳族环（如酯和酰胺），可观察到出色的转化率。发现富电子体系，包括甲基和甲氧基取代的芳基氯，反应性较低。此外，当杂芳基氯化物进入交叉偶联方案时，发现该反应是最成功的。通过映射取代基对反应选择性的影响，我们能够证明缺电子的芳基氯对于有效偶联是必不可少的，并使用电子结构计算通过估计每种芳基氯的电子亲和力来预测成功偶联的可能性。使用选定的芳基氯化物可达到中等程度的分离收率，对于所有偶合的杂芳基氯化物，获得中等至良好的分离产率。当使用2,6-二氯喹啉时，观察到极好的选择性，可在具有挑战性的底物上单取代。
• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Blaney Jeffrey

  公开号：US20120022043A1

  公开（公告）日：2012-01-26

  The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

  该发明提供了Formula Ia的JAK激酶抑制剂，其对映体、二对映体或其药学上可接受的盐，其中R1、R2、R7和Z在此处定义，包括Formula Ia化合物和药学上可接受的载体、辅料或载体的药物组合物，以及治疗或减轻对JAK激酶活性抑制有响应的疾病或病况的方法。
• NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：SEONG Churlmin

  公开号：US20090258876A1

  公开（公告）日：2009-10-15

  Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT 2c receptors, act selectively on the 5-HT 2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT 2c receptors.

  本公开涉及一种新的吲哚羧酸双吡啶羧酰胺衍生物，其制备方法，以及包含该衍生物作为活性成分的用于预防或治疗肥胖、泌尿系统疾病和中枢神经系统疾病的组合物。根据本发明的吲哚羧酸双吡啶羧酰胺衍生物具有高亲和力5-HT2c受体，对5-HT2c受体选择性作用，这些衍生物很少出现由其他受体引起的不良反应。由于这些衍生物有效抑制5-羟色胺活性，它们可能对治疗或预防肥胖；泌尿系统疾病，如尿失禁、早泄、勃起功能障碍和前列腺增生；以及与5-HT2c受体相关的中枢神经系统疾病，如抑郁症、焦虑症、关注症、恐慌症、癫痫、强迫症、偏头痛、睡眠障碍、戒毒、阿尔茨海默病和精神分裂症可能有用。
• [EN] INDOLIN-2-ONE DERIVATIVES FOR USE IN THE TREATMENT OF CNS AND RELATED DISORDERS<br/>[FR] DÉRIVÉS INDOLIN-2-ONE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU SNC ET DE TROUBLES APPARENTÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017076931A1

  公开（公告）日：2017-05-11

  The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein A is phenyl or a six membered heteroaryl group, containing one or two N atoms, selected from or the oxygen atom may form together with two neighboring carbon atoms from the group A an additional fused ring, selected from or; R1 is hydrogen, lower alkyl, lower alkyl substitututed by halogen or oxetanyl; R2 is hydrogen, lower alkyl lower alkoxy, halogen or cycloalkyl; the dotted line is nothing or may be –CH2-; as well as with a pharmaceutically acceptable salt thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive- compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co morbid epilepsy.

  本发明涉及一般式（I）中的吲哚啉-2-酮衍生物，其中A是苯基或含有一个或两个N原子的六元杂环基，选择自或氧原子可与基团A中的两个相邻碳原子形成一个额外的融合环，选择自或；R1是氢、较低烷基、受卤素或氧乙烯基取代的较低烷基；R2是氢、较低烷基、较低烷氧基、卤素或环烷基；虚线是不存在或可能是-CH2-；以及其药学上可接受的盐、消旋混合物、相应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗与精神病（精神病）、精神分裂症的阳性和阴性症状、物质滥用、酒精和药物成瘾、强迫症、认知障碍、躁郁症、情感障碍、重度抑郁症、治疗难治性抑郁症、焦虑症、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、神经退行性疾病、睡眠障碍、慢性疲劳综合征、僵硬、炎症性疾病、哮喘、亨廷顿病、注意缺陷多动障碍、肌萎缩侧索硬化、关节炎、自身免疫疾病、病毒和真菌感染、心血管疾病、眼科学和炎症性视网膜疾病以及平衡问题、癫痫和伴发癫痫的神经发育障碍相关的中枢神经系统疾病的治疗。